Abstract
Hepatocellular carcinoma (HCC) tumors with NRF2 and ARID1A mutations have more aggressive phenotypes and result in a reduced response to trans-arterial embolization (TAE). Pathway analysis of differentially expressed genes of these tumors may reveal epigenetic modifications that impact embolization response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
